跳至主要内容
临床试验/ITMCTR2024000197
ITMCTR2024000197尚未招募1 期

A study on the clinical efficacy of Ginseng-Astragalus Delayed Failure Formula in treating frailty syndrome in the elderly

Xiyuan Hospital of China Academy of Chinese Medical Sciences0 个研究点开始时间: 待定最近更新:

试验速览

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
60 至 85(—)
性别
All

入选标准

  • (1) Meets the diagnostic criteria for Fried frailty.
  • (2) Comply with the diagnostic criteria of spleen qi deficiency in traditional Chinese medicine.
  • (3) Age 60-85 years old, gender is not limited.
  • (4) Volunteer subjects signed an informed consent form.
  • (5) The frailty patients are combined with chronic diseases, such as hypertension, diabetes mellitus, coronary heart disease, etc., and are treated with routine medication.
  • Physical examination and auxiliary examination show that the control is effective, can be included.
  • (6) Patients with malignant tumours who have been evaluated as CR (complete remission) after treatment and whose treatment has ended 3 years after enrolment.

排除标准

  • (1) Patients who cannot co-operate with the assessment due to cognitive impairment, limitation of voluntary activities, etc;
  • (2) Patients with cardiovascular, cerebrovascular, digestive, respiratory, haematological, neurological and endocrine metabolic diseases who have been hospitalised twice in the past year.
  • (2) Patients with cardiovascular, cerebrovascular, digestive, respiratory, haematological, neurological and endocrine metabolic diseases who have been hospitalised twice in the past 1 year and whose conditions are often unstable;
  • (3) Patients with malignant tumour, whose evaluation is not CR, and who are clinically recommended for surgical/non-surgical treatment;
  • (4) Patients with liver and renal insufficiency, abnormal transaminases and creatinine;
  • (5) In addition to the above diseases, due to the combination of other diseases currently treatment can not be interrupted, or the need for repeated hospitalisation can not cooperate with the
  • Regular treatment;
  • (6) Patients participating in other clinical trials;
  • (7) Patients who are allergic to the drugs in this formula;
  • (8) Patients who are using hormone therapy for other diseases.

研究者

相似试验